Sustained antiplatelet properties of nitroglycerin during hemodynamic tolerance in rats

Journal of Cardiovascular Pharmacology

Volumn 28, Issue 3, 1996, Pages 432-438

  Booth, Brian P ^a   Jacob, Saji ^b   Bauer, John A ^a   Fung, Ho Leung ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bleeding time; Cyclic GMP; Nitric oxide; Nitroglycerin; Platelets; Tolerance

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYCLIC GMP; GLYCERYL TRINITRATE; ISOBUTYLMETHYLXANTHINE; KETAMINE; N ACETYL S NITROSOPENICILLAMINE; NITRATE; NITRIC OXIDE; XYLAZINE;

ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; HEART INFARCTION; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE AGGREGATION; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANIMALS; BLOOD PLATELETS; CYCLIC GMP; DRUG TOLERANCE; HEMATOCRIT; HEMODYNAMIC PROCESSES; MALE; NITROGLYCERIN; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 0029815891     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199609000-00013     Document Type: Article

References (56)

1. Murrell E. Nitroglycerine as a remedy for angina pectoris. Lancet 1879;1:80-1.
2. Armstrong PW, Armstrong J, Marks GS. Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive heart failure. Circulation 1980;62:160-6.
3. Epstein SE, Kent KM, Goldstein RE, Borer JS, Redwood DR. Reduction of ischemic injury by nitroglycerin during acute myocardial infarction. N Engl J Med 1975;292:29-35.
4. Jugdutt BI. Intravenous nitroglycerin infusion in acute myocardial infarction: myocardial salvage. Cardiovasc Res Rep 1984;5:1145-63.
5. Schelling JL, Lasagna L. A study of cross-tolerance to circulatory effects of organic nitrates. Clin Pharmacol Ther 1967;8:256-60.
6. Parker JO, Fung H-L, Ruggeriello D, Stone JA. Tolerance to isosorbide dinitrate: rate of development and reversal. Circulation 1983;68:1074-80.
7. Bussman WD. Nitrate patches: duration of action and loss of efficacy; reflections on the nitrates' mode of action. Eur J Clin Pharmacol 1990;38:s27-9.
8. Silber S. Nitrates: why and how they should be used today? Eur J Pharmacol 1990;38:s35-51.
9. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther 1973; 184:709-15.
10. Chung SJ, Fung H-L. Relationship between nitroglycerin-induced vascular relaxation and nitric oxide production: probes with inhibitors and tolerance development. Biochem Pharmacol 1993;45:257-63.
11. Waldman SA, Rapoport RM, Ginsburg R, Murad F. Desensitization to nitroglycerin in vascular smooth muscle from rat and human. Biochem Pharmacol 1986;35:3525-31.
12. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushack M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
13. Dupuis J, Lalonde G, Lemieux R, Rouleau JL. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-31.
14. Parker JD, Farrell B, Fenton T, Cohanim M, Parker JO. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-45.
15. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular Superoxide anion production in nitrate tolerance. J Clin Invest 1995;95:187-94.
16. Munzel T, Giaid A, Kurz S, Stewart DJ, Harrison DG. Evidence for the role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA 1995;92: 5244-8.
17. Fung H-L. Solving the mystery of nitrate tolerance: a new scent on the trail? Circulation 1993;88:322-4.
18. Stamler J, Cunningham M, Loscalzo J. Reduced thiol and the effect of intravenous nitroglycerin on platelet aggregation. Am J Cardiol 1988;62:377-80.
19. Diodati J, Theroux P, Latour JG, Lacoste L, Lam JYT, Waters D. Effects of nitroglycerin at therapeutic doses on platelet aggregation in unstable angina pectoris and myocardial infarction. Am J Cardiol 1990;66:683-8.
20. Chirkov YY, Naujalis JI, Sage E, Horowitz JD. Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol 1993; 21:384-9.
21. Watanabe H, Kakihana M, OhtsukaS, Enomoto T, Yasui K, Sugishita Y. Platelet cGMP: a potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993;88:29-36.
22. Mohrman DE, Heller LJ. Cardiovascular physiology, 3rd ed. New York:McGraw-Hill, 1991.
23. Rybak MEM, Renzulli LA. A liposome based platelet substitute, the plateletsome, with hemostatic efficacy. Biomat Artif Celts Immob Biotechnol 1993;21:101-18.
24. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988; 77:1376-84.
25. Katz RJ, Levy WS, Buff L, Wasserman AG. Prevention of nitrate tolerance with angiotensin converting enzyme inhibitors. Circulation 1991;83:1271-7.
26. Parker JD, Farrell B, Fenton T, Parker JO. Effects of diuretic therapy on the development of tolerance during continuous therapy with nitroglycerin. J Am Coll Cardiol 1992; 20:616-22.
27. Wiegand A, Bauer KH, Trenk D, Jahnchcn E. Pharmacodynamic and pharmacokinetic evaluation of a new transdermal delivery system with time-dependent release of glyceryl trinitrate. J Clin Pharmacol 1992;32:77-84.
28. Kowaluk EA, Poliszczuk R, Fung H-L. Tolerance to relaxation in rat aorta: comparison of an S-nitrosothiol with nitroglycerin. Eur J Pharmacol 1987;144:379-83.
29. Kowaluk EA, Fung H-L. Dissociation of nitrovasodilator-induced relaxation from cGMP levels in vitro nitrate tolerance. Eur J Pharmacol 1990;176:91-5.
30. Bauer JA, Fung H-L. Differential hemodynamic effects of and tolerance properties of nitroglycerin and 5-nitrosothiol in experimental heart failure. J Pharmacol Exp Ther 1991; 256:249-54.
31. Bennett BM, Schoder H, Hayward LD, Waldman SA, Murad F. Effect of in vitro organic nitrate tolerance on relaxation, cyclic GMP accumulation and guanylate cyclase activation by glyceryl trinitrate and enantiomers of isoidide dinitrate. Circ Res 1988;63:693-701.
32. Haj-Yehia A, Benet LZ. Dissociation of tissue thiol content from nitroglycerin induced cyclic-3′;,5′-guanosine monophosphate and the state of tolerance: in vivo experiments. J Pharmacol Exp Ther 1995;273:94-100.
33. Hebert D, Lam JYT, Walters D. Persistent anti-thrombotic effects of continuous nitroglycerin therapy despite hemodynamic tolerance. Circulation 1993;88:1-347.
34. Hebert D, Lam JYT, Moura A. Absence of rebound thrombosis after cessation of continuous nitroglycerin treatment. Circulation 1994;90:I-28.
35. Curfman GD, Heinsimer JA, Lozner EC, Fung H-L. Intravenous nitroglycerin in the treatment of spontaneous angina pectoris: a prospective, randomized trial. Circulation 1983; 67:276-82.
36. Weber AA, Strobach H, Schror K. Direct inhibition of platelet function by organic nitrates via nitric oxide formation. Eur J Pharmacol 1993;247:29-37.
37. Feelisch M, Brands F, Kelm M. Human endothelial cells bioactivate organic nitrates to nitric oxide: implications for the reinforcement of endothelial defence mechanisms. Eur J Clin Invest 1995;25:737-45.
38. Fortunate JS, Pinheiro MJ, Monteiro MC, Rodrigues MA, Amaral I. Acute effects of adrenaline on platelet aggregation and kinetics in vivo. J Nucl Biol Med 1991;35:105-10.
39. Munro JM, Cotran RS, Biology of disease. The pathogenesis of atherosclerosis: atherogenesis and inflammation. Lab Invest 1988;58:249-61.
40. Friedman RJ, Stemerman MB, Wenz B, et al. The effect of thrombocytopenia on experimental arteriosclerotic lesion formation in rabbits: smooth muscle cell proliferation and re-endothelialization. J Clin Invest 1977;60:1191.
41. Roy LF, Ogilvie RI, Larochelle P, Hamet P, Leenen FHH. Cardiac and vascular effects of atrial natriuretic factor and sodium nitroprusside in healthy men. Circulation 1989:79:383-92.
42. Tsutamoto T, Kinoshita M, Ohbayashi Y, Wada A, Maeda Y, Aadachi T. Plasma arteriovenous cGMP difference as a useful indicator of nitrate tolerance in patients with heart failure. Circulation 1990;90:823-9.
43. Karrenbrock R, Heim JM, Gerzer R. Effect of molsidimine on ex vivo platelet aggregation and plasma guanosine 3′:5′-cyclic monophosphate levels in healthy volunteers. Klin Wochenschr 1990;68:213-7.
44. Gerzer R, Tremblay J, Pang S, DeLean A, Hamet P. Atrial natriuretic factor activates mammalian participate guanylate cyclase. Fed Proc 1985;44:698.
45. Field M, Graf LH, Laird WJ, Smith PL. Heat-stable enterotoxin of Escherichia coli: in vitro effects on guanylate cyclase activity, cyclic GMP concentration and ion transport in small intestine. Proc Natl Acad Sci USA 1978;75:2800-4.
46. Small M, Lowe GDO, Cameron E, Forbes CD. Contribution of hematocrit to bleeding time. Haemostasis 1983;13:379-84.
47. Lethagen S, Kling S. New bleeding time devices with retractable blades evaluated in children, healthy volunteers and patients with prolonged bleeding time. Thromb Haemost 1993;70:595-7.
48. De Caterina R, Lanza M, Manca G, Strata GB, Maffei S, Salvatore L. Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 1994;84:3363-70.
49. Hellem AJ, Borchgrevink CF, Ames SB. The role of red cells in haemostasis: the relation between haematocrit, bleeding time and platelet adhesiveness. Br J Haematol 1961;7:42-50.
50. Harker LA, Slichter SJ. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 1972; 287:155-9.
51. 2 with the length of bleeding time. Clin Invest Med 1989;12:165-71.
52. Suehiro A, Oura Y, Ueda M, Kakishita E. Correlation between bleeding time and antithrombotic effect of platelet-suppressive agents in rat experimental model. Res Commun Chem Pathol Pharmacol 1994;83:157-63.
53. Buerke M, Pittroff W, Meyer J, Darius H. Aspirin therapy: optimized platelet inhibition with different loading and maintenance doses. Am Heart J 1995;130:465-72.
54. Lichtenthal PR, Rossi E, Louis G, et al. Dose-related prolongation of the bleeding time by intravenous nitroglycerin. Anesth Analg 1985;64:30-3.
55. Ring T, Knudsen F, Kristensen SD, Larsen CE. Nitroglycerin prolongs bleeding time in healthy males. Thromb Res 1983;29:553-9.
56. Keaney JF, Simon DI, Stamler JS, et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 1993;91:1582-9.